All News
Diagnosis and Management of Kawasaki Disease
EurekAlert!
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and treatment options for children and adults with this condition.
Read Article
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Dot the "i", Cross the "t" (10.11.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0
Links:
Eric Dein ericdeinmd ( View Tweet)
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV
Links:
Richard Conway RichardPAConway ( View Tweet)
EGPA: To RTX or not to RTX?
French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy
Huge anticipation for these results, hopefully next year!
#ACR24 @RheumNow https://t.co/POelLpirrI
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Year in review:
The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA
@RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB
Links:
sheila RHEUMarampa ( View Tweet)
Looking forward to this Plenary - upadacitinib vs plbo in GCA
Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks
Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉
#ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI
Links:
Mike Putman EBRheum ( View Tweet)
MANDARA
Mepolizumab v benralizumab for EGPA
BEN is non-inferior
Secondary outcomes- less eosinophils and more pts completely off GCs
Now approved for EGPA
Year in Review #ACR24 Pillinger
@RheumNow https://t.co/ThLziABvzu
Eric Dein ericdeinmd ( View Tweet)
Abatacept for GPA?
Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA
Continued need for tx options in non-severe relapsing dz
@RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Literature review of the treatment of IgA Vasculitis (Henoch–Schönlein Purpura) suggests:
- Glucocorticoids are 1st -line therapy, esp if severe
- For minor HSP: colchicine, dapsone, & methotrexate may be useful
- Also studied cyclosporine A, tacrolimus, MMF… https://t.co/ZoZX3kyHvo https://t.co/dS82ekuEkv
Dr. John Cush RheumNow ( View Tweet)
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis https://t.co/luhFvy3yjR https://t.co/52oiTYG3a4
Dr. John Cush RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/2Om0IIFVnG https://t.co/W7mbdPh9ee
Dr. John Cush RheumNow ( View Tweet)
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq
Dr. John Cush RheumNow ( View Tweet)
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Links:
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Genomic profiling of 34 ANCA-assoc vasculitis pts w/ glomerulonephritis suggests activity by cytokine-producing CD4+ & CD8+ T cells & potential for ustekinumab. 4 relapsing GN pts Rx w/ UST & CTX +steroids, w/ good responses, improved GFR and BVAS scores… https://t.co/ospA8CJ6JE https://t.co/HbRpXMec0f
Dr. John Cush RheumNow ( View Tweet)
Pneumocystis Jirovecii Pneumonia Complicating Systemic Vasculitis
A retrospecitive analysis of 62 patients with systemic vasculitis complicated by Pneumocystis jirovecii pneumonia (PJP) showed those with MPA had a higher mortality risk, possibly due to a higher prevalence of… https://t.co/yWjWOXtMwR https://t.co/2aD3EIsi7z
Dr. John Cush RheumNow ( View Tweet)
VASCULTIS Literature analysis shows most frequent citations, research centers and reveals the top 3 vasculitis topics to be:
1. Immune checkpoint inhibitors
2. GPA/Wegener's granulomatosis
3. SLE - lupus vasculopathy
https://t.co/FS2cuv9gt4 https://t.co/ziI4sfexrm
Dr. John Cush RheumNow ( View Tweet)
British Society Guidelines for Managing Behçet’s Disease
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in… https://t.co/4Q1Ac60Dyp https://t.co/Qj3sQQ8SnJ
Dr. John Cush RheumNow ( View Tweet)
